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What is ChIP-seq?
ChIP-seq  is  short  for  chromatin  immunoprecipitation-
sequencing. Fundamentally, ChIP-seq is the sequencing 
of the genomic DNA fragments that co-precipitate with a 
DNA-binding  protein  that  is  under  study.  The  DNA-
binding proteins most frequently investigated in this way 
are  transcription  factors  (for  example,  p53  or  NFκB), 
chromatin-modifying  enzymes  (for  example,  p300, 
histone deacetylases), modified histones interacting with 
genomic DNA (for example, histone 3 trimethylated on 
lysine  4),  and  components  of  the  basal  transcriptional 
machinery (for example, RNA polymerase II). Theoreti-
cally, this technology can identify, in an unbiased manner, 
all  DNA  segments  in  the  genome  physically  associated 
with a specific DNA-binding protein. We say ‘unbiased’ 
because  whatever  DNA  comes  down  in  the  immuno-
precipitate will be sequenced, and thus the technique does 
not rely on prior knowledge of precise DNA binding sites.
What can I learn by knowing the DNA binding sites 
of proteins such as transcription factors?
Quite a bit. The major function of a transcription factor 
is to recognize and bind to specific sites in the genome, to 
recruit cofactors, and thus to regulate transcription. The 
first action of a transcription factor is to find and to bind 
DNA segments and ChIP-seq allows the binding sites of 
transcription  factors  to  be  identified  across  entire 
genomes. The DNA sequence motif that is recognized by 
the  binding  protein  can  be  computed;  the  precise 
regulatory  sites  in  the  genome  for  any  transcription 
factor can be identified; the direct downstream targets of 
any  transcription  factor  can  be  determined;  and  the 
clustering of transcription-regulatory proteins at specific 
DNA sites can be assessed.
How is it done?
The first step depends on the proteins under investigation 
(Figure 1). For many protein-DNA interactions, particu  larly 
for transiently bound factors, the first step might be to fix 
the interaction using formaldehyde as a cross-linker. This 
may  not  be  necessary,  however,  for  localizing  histone 
modifications  or  for  simply  determining  nucleo  some 
positioning,  because  the  histone-DNA  interactions  are 
generally strong enough to be maintained without using a 
cross-linking agent, and in this case a native ChIP (n-
ChIP) without cross-linking might be preferable [1]. In 
the  case  of  chromatin-remodeling  enzymes  such  as 
histone  deacetylases  (HDACs)  or  histone  acetyl  trans-
ferases  (HATs),  an  additional  cross-linking  step  (using 
disuccinimidyl  glutarate)  can  be  included,  to  preserve 
protein-protein  complexes  before  cross-linking  with 
formaldehyde [2]. After cross-linking, the chromatin is 
fragmented into pieces of about 150 to 500 bp. For ChIP 
of  transcription  factors  and  under  cross-linked  condi-
tions  this  is  done  using  sonication.  It  is  important  to 
achieve  sufficient  and  reproducible  fragmentation,  as 
preparation  of  the  subsequent  library  of  fragments  for 
sequencing requires fragment sizes of 200 to 300 bp. In the 
case  of  n-ChIP,  the  DNA  is  digested  with  micrococcal 
nuclease to give a slightly better resolution, as it will leave 
the nucleosome as the smallest unit (approximately 150 bp).
After fragmentation, the next step is immuno  precipi-
tation,  using  a  specific  antibody  against  the  protein  of 
interest.  The  success  of  a  ChIP-seq  project  depends 
crucially on strong enrichment of the chromatin specifi-
cally bound by the protein under study. We routinely test 
a  number  of  antibodies  and  choose  the  one  with 
consistently high enrichment of DNA at a known binding 
site when compared with the DNA immunoprecipitated 
by a nonspecific control antibody such as anti-IgG and no 
enrichment at negative control sites.
Once  the  enrichment  is  convincing,  the  material  is 
ready to be sequenced. If the amount of material is not a 
limiting factor (for example, when it comes from a tissue 
culture) the amount of DNA used for library preparation 
is about 10 to 15 ng. If the sequencing platform requires 
the incorporation of linkers and involves a PCR ampli-
fication step, this can be a considerable source of bias 
[3,4], and it is advisable to keep the number of cycles as 
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fragments  of  200  to  300  bp  long  are  selected  and 
sequenced.  Cross-contamination  is  a  risk,  both  before 
PCR and afterwards, but can be minimized by preparing 
only a very small number of libraries in parallel and using 
separate gels when purifying the amplified libraries.
When material is limited, which is often the case with 
primary cell or tissue samples, smaller starting amounts 
of DNA have to be used. This is usually at the cost of 
additional  rounds  of  amplification,  which  introduces 
amplification biases. However, one way of avoiding this 
might  be  to  use  the  Helicos  next-generation  single-
molecule  sequencing  platform,  which  can  generate  a 
sequencing library from 50 pg of starting material with-
out requiring amplification [4].
Finally, the short sequenced fragments (known as tags) 
are computationally mapped by alignment to a reference 
genome and regions of enriched tag counts are identified, 
a step known as peak-calling.
Why is ChIP-seq better than older approaches to 
finding DNA binding sites?
ChIP itself has been around for a while. This is where a 
DNA-binding  protein  is  immunoprecipitated  with  its 
cognate  DNA  and  the  presence  of  DNA  binding  at  a 
specific site is assessed by quantitative PCR. The problem 
with this approach is that only predetermined individual 
sites of known sequence can be studied.
An alternative technique that overcomes this limitation 
is DAM-ID, in which the protein of interest is fused to 
the  Escherichia  coli  DNA  adenine  methyltransferase 
(DAM). When this fusion protein is expressed in cells, 
the adenines in the DNA adjacent to its binding site will 
be  methylated.  These  sites  can  then  be  identified  by 
methylation-sensitive restriction endonuclease mapping. 
But  this  technique  is  cumbersome,  and  requires  over-
expressing  an  artificial  construct,  limiting  analysis  to 
transfectable cell lines.
These  problems  are  avoided  in  ChIP-chip,  in  which 
ChIP  is  coupled  to  DNA  hybridization  array  (chip) 
technology. The DNA bound by the protein of interest is 
hybridized to a DNA microarray with probes that cover 
either  the  entire  genome,  or  specific  portions  of  the 
genome  (for  example,  promoter  regions).  This  is  the 
closest  methodology  to  ChIP-seq,  but  its  mapping 
precision is lower, and the dynamic range of the readout 
is significantly less. The resolution and sensitivity of the 
two techniques are compared in Figure 2. Moreover, all 
hybridization approaches mask repetitive sequences. We 
have  found  that  a  significant  portion  (between  10  and 
30%) of functional transcription factor binding sites are 
within repeats and are lost when ChIP-chip is used [5]. 
However, we still use ChIP-chip with custom arrays when 
specific  binding  sites  are  to  be  interrogated  repeatedly 
over many experimental conditions.
What are the technical problems with ChIP-seq?
Roughly  speaking,  ChIP-seq  has  three  key  steps  that 
determine its success. The first and most crucial is anti-
body  selection;  the  second  is  the  actual  sequencing, 
which is subject to several possible biases; and the third 
is  the  algorithmic  analysis,  including  mapping  and 
peak-calling.
The first requirement, obviously, is that the antibody 
has some specificity for the protein under study: this can 
be tested using a panel of recombinant proteins or cell 
lines transfected with different protein targets. Then, the 
antibody must be able to immunoprecipitate the target 
protein. Not all antibodies immunoprecipitate, and even 
when  they  do,  they  may  not  do  well  in  ChIP.  Ideally, 
earlier studies will have identified genomic sites where 
Figure 1. Flow scheme of the central steps in the ChIP-seq 
procedure.
ChIP Library construction Sequencing
Analysis and visualization Peak calling Alignment
Figure 2. Comparison of ChIP-seq and ChIP-chip. Representative 
signals from ChIP-seq (solid line) and ChIP-chip (dashed line) show 
both greater dynamic range and higher resolution with ChIP-seq. 
Whereas three binding peaks are identified using ChIP-seq, only one 
broad peak is detected using ChIP-chip.
Chromosomal position
Sequence tag counts or
fluorescence intensity
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to optimize the ChIP conditions.
The second issue is sequencing, which is a ‘black box’ 
for many biologists, who are familiar with what goes in 
and what comes out, but perhaps not with the possible 
biases introduced in between. Next-generation sequen-
cing  approaches  require  bulk  processing  of  DNA 
fragments and massively parallel sequencing. This means 
that even the slightest bias in the ligation of linkers, in 
PCR  amplification,  or  in  hybridization  might  result  in 
some platform-dependent biases in the population data 
emerging  from  10  million  or  more  reads.  The 
technologies are still evolving and the different formats 
have different biases. For this reason, it is important in a 
ChIP-seq experiment to run a control using ‘input DNA’ 
(non-ChIP genomic DNA) so that sequencing biases can 
be identified and adjusted for.
The  third  issue  is  mapping,  which  with  short  tags 
(around 25 to 35 bp) can be ambiguous in regions of high 
homology or in repeat regions. As the tag sequences get 
longer,  this  is  less  of  a  problem,  but  base  calling  and 
sequencing  errors  then  limit  the  mappability.  It  is  not 
uncommon  to  have  only  50%  of  the  reads  mappable, 
though with more ‘intelligent’ mapping algorithms that 
take into account sequencing errors or polymorphisms, 
mappability has increased significantly. In ChIP-seq, the 
density of mapped sequence tags is a prime determinant 
of success. Illumina’s ELAND algorithm and the MAQ 
(Mapping  and  Assembly  with  Quality)  used  to  be  the 
short-read mappers of choice, but a new generation of 
more efficient programs such as Bowtie, BWA (Burrows-
Wheeler  Alignment  Tool)  and  BFAST  (Blat-like  Fast 
Accurate Search Tool) are gradually superseding them.
That leaves peak-calling - how is that done?
There is now a large number of free and commercial peak-
calling software packages. Peak-calling algorithms look for 
‘peaks’  -  regions  of  significant  tag  enrichment  that  are 
typically assumed to reflect transcription factor binding to 
the region. While some packages simply aggregate mapped 
tags  without  regard  to  strand,  others  use  strand 
information  to  locate  the  peaks  more  sensitively.  Some 
peak-calling algorithms require the user to supply a control 
library whereas others can work without one, but there are 
several known sources of bias in sequencing reads with 
ChIP-seq, so that the estimation of confidence in the peaks 
without a control library is highly unreliable and should be 
avoided [6]. Confidence in the peaks is quantified using 
measures such as P-value or false discovery rate (FDR), 
typically based on comparisons of the ChIP library and the 
control  library,  though  different  peak-calling  packages 
differ in exactly how this is done.
Some  publicly  available  peak-calling  algorithms  are 
listed  in  Table  1  and  several  excellent  and  detailed 
reviews are available [7-9], although differences in perfor-
mance  between  peak-callers  are  not  well  understood 
[9,10]. Other packages not listed in the table include GLITR, 
USeq,  QuEST,  CisGenome,  Vancouver  Short  Read 
Analysis  Package,  spp,  CCAT,  ERANGE  and  ZINBA. 
Many commercial software packages also contain peak-
calling functionality.
What are the sources of bias in the sequencing 
reads that you mentioned?
Many kinds of systematic biases have been described in 
next-generation sequencing in general and ChIP-seq in 
particular. A preference for sequencing C+G rich regions 
has been found for some platforms [11]. Mapping bias 
results  from  the  frequency  of  occurrence  of  particular 
short homologous sequences in the genome, and from 
genomic amplifications and repeats. Hence the need for a 
control library, commonly generated by sequencing input 
DNA (non-ChIP genomic DNA). However, certain biases 
seem to remain even in the control library; in particular, 
genomic landmarks such as transcription start sites tend 
to have higher read counts even in control libraries [12]. 
Chromatin  structure  also  introduces  biases  into  the 
physical manipulation of DNA in ChIP experiments as a 
result of non-uniform shearing [13]. Specifically, silenced 
chromatin is harder to shear than euchromatin and will 
thus be underrepresented in sequence reads. So regions 
in transcribed genes appear to be more represented than 
in silent genes. Some protocols use a PCR step, which may 
lead to the spurious replication of reads. Therefore, most 
workflows filter out multiple identical copies of reads.
All  mapping  algorithms  seek  to  normalize  the 
background  in  such  a  way  as  to  reduce  the  bias  in 
reporting. As we have already said, the best approach is 
to have an input DNA control from cells being studied, 
although some protocols seek internal normalization by a 
sampling  strategy.  In  cancer  cell  lines,  regions  of  gene 
amplification can pose a further problem. False-positive 
peak  calls  are  common  in  amplified  regions  simply 
because  those  regions  are  overrepresented  in  the 
genomic DNA sample. Amplified regions can be ‘flagged’ 
Table 1. Peak-calling algorithms for ChIP-seq
Name of algorithm  Notable features
MACS [23]   Uses both a control library and local statistics to  
  minimize bias
SICER [14]  Designed for detecting diffusely enriched regions;  
  for example, histone modification
PeakSeq [24]   Corrects for reference genome mappability and  
  local statistics
SISSRs [25]   High resolution, precise identification of binding- 
  site location
F-seq [26]   Uses kernel density estimation
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estimated copy number. However, unless the sample has 
been sequenced very deeply, high sampling noise in reads 
from these regions - for both ChIP and control libraries - 
may yield unreliable estimates for the copy number and 
subsequently  unreliable  normalized  values.  Thus,  even 
normalization will not be sufficient to reduce the false 
positives to a baseline level. While this may be acceptable 
if  discovery  of  individual  binding  sites  (followed  by 
experimental validation) is the goal, using whole-genome 
binding sites in order to build a sequence-based model of 
transcription  factor  binding  may  require  complete 
masking  of  amplified  regions  in  the  model  building  to 
reduce the effect of noisy input data.
When do you know a ChIP-seq is not working?
If there is a control library, a ChIP-seq that is not working 
should  result  in  few  called  peaks,  and  side-by-side 
inspection  of  selected  genomic  loci  in  the  ChIP  and 
control libraries should show poor enrichment. However, 
even when two identical libraries are sequenced, there will 
be  several  areas  that  may  show  significant  count 
differences (as part of an FDR). The ultimate test would be 
the  quantitative  PCR  validation  of  selected  ChIP-seq 
peaks. For some transcription factors with well charac  ter-
ized motifs it can make sense to check for the occur  rence 
of the motif in a significant fraction of the called peaks.
You said ChIP-seq could be used for genomic 
analysis of histone modifications - but surely that 
can’t be done by mapping short sequences?
It is true that most peak-calling algorithms are designed 
with  transcription  factors  in  mind,  and  such  factors 
usually bind to short sequence elements (on the order of 
10 bp). Histone marks are sometimes diffusely enriched 
over several nucleosomes (hundreds of base pairs) or in 
some cases thousands or tens of thousands of base pairs. 
This means that peaks may be over-called in a histone-
modification-enriched region (that is, the algorithm calls 
several peaks where a human would prefer to view the 
whole region as an enriched unit) or the algorithm may 
fail to detect an enriched region where there is a subtle 
but consistent enrichment but where no single locus is 
enriched enough to count as a ‘peak’ according to the 
algorithm’s criteria. There may also be apparent gaps in 
regions that are actually enriched, as a result of insuf-
ficiently deep sequencing. To avoid this, the parameters 
for peak-calling must be appropriately tuned.
How  to  do  the  tuning  depends  on  the  intended 
application.  Sometimes  it  may  be  enough  to  compute 
correlation statistics for read counts with genomic land-
marks such as genes, or to calculate average tag-density 
profiles  around  a  set  of  such  landmarks.  If  a  precise 
demarcation  of  the  histone-mark-enriched  regions  is 
needed,  one  could  use  a  peak-calling  package  with 
explicit  support  for  longer  and  more  diffuse  enriched 
regions, such as SICER [14] or CCAT [15].
How do you know when you have sequenced 
enough?
The basic question is whether a library has reached the 
asymptotic  saturation  point  beyond  which  no  new 
binding sites will be discovered. One can try to estimate 
binding  saturation  by  simulation.  By  running  a  peak-
calling algorithm on successively smaller random subsets 
of  the  set  of  sequence  reads,  the  number  of  detected 
peaks (on the y axis) can be plotted against the number of 
reads  (on  the  x  axis).  This  will  often  (but  not  always) 
result in a curve that rises rapidly in the beginning but 
then starts to saturate. The curve can be extrapolated to 
estimate at what number of sequenced reads it will start 
to appear flat. Estimating the exact saturation point in 
this way may not be possible in a strict sense, but it is 
usually  enough  to  get  an  approximation.  Obviously,  a 
factor  that  binds  more  diffusely,  such  as  some  histone 
marks, will need more sequence to reach saturation. A 
curious  observation  is  that  some  DNA-binding  factors 
(such  as  RNA  polymerase  II)  have  clear  saturation 
characteristics but for others saturation is less obvious. 
Although the exact reason for this is unclear, it may be 
that there are two populations of binding sites, one with 
high affinity and a second with lower affinity and greater 
recognition sequence degeneracy that is therefore more 
abundant in the genome. More sequencing will primarily 
uncover more sites of the lower-affinity class. Thus, for 
practical  purposes,  it  may  be  more  realistic  to  aim  to 
predict  the  number  of  tags  required  to  saturate  the 
detection of peaks above a given target enrichment ratio 
(minimal enrichment saturation ratio, MSER) [16].
Can one library be compared quantitatively with 
another on a site-by-site basis?
Often  it  is  desirable  to  assess  changes  in  transcription 
factor  binding  on  a  genomic  scale  over  time  or  after 
ligand  activation  as  in  the  case  of  nuclear  hormone 
receptors.  To  accomplish  this,  multiple  ChIP-seqs  will 
need to be performed over time and the quantification of 
transcription factor occupancy at each site compared. In 
theory one should be able to compare two libraries side 
by side. However, one should keep in mind the biases that 
can give rise to differences between the libraries. These 
include differences in DNA fragmentation protocol, time 
of cross-linking, the sequencing platform, and the soft-
ware  and  parameters  used  in  mapping.  Pre-processing 
steps,  such  as  removing  identical  reads  and  amplified 
regions (see above), must also be done in a consistent 
way [17]. Finally, the depth of the sequencing reads needs 
to be comparable as tag counts at each peak and even the 
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sequenced.
What can be learned using ChIP-seq?
A  concrete  contribution  has  been  the  identification  of 
new  regulatory  elements  -  for  example,  new  tissue-
specific  enhancers  have  been  identified  using  p300-
binding sites in the mouse brain [18]. ChIP-seq studies 
on histone modifications [1,19] have yielded insights into 
the functional organization of the genome on a scale that 
was  previously  unattainable.  Using  the  genome-wide 
information  about  functional  domains  as  defined  by 
histone modifications, Guttman et al. [20] predicted and 
validated many large non-coding RNAs.
Perhaps the most important contribution of ChIP-seq 
approaches, however, is in providing a ‘population’ analysis 
of protein-DNA interactions on a genomic scale. This has 
shown  how  individual  transcription  factors  employ 
different  mechanisms  for  gene  regulation  depending  on 
the degeneracy of the binding-site recognition motif, the 
presence of other co-localized transcription factors, and 
the  distance  from  the  transcription  start  site.  In  many 
cases  the  mechanism  of  gene  regulation  by  a  given 
transcription factor is specific to each particular binding 
site.  Only  through  the  analysis  of  the  entire  range  of 
binding sites in the genome could some higher functional 
principles be discerned. As an example, ChIP-seq profiling 
of  13  transcription  factors  in  embryonic  stem  (ES)  cell 
development  revealed  the  organization  of  regu  la  tory 
elements  into  ‘enhanceosomes’  [21].  This  infor  mation 
provided insights in the integration of transcrip  tion factor-
mediated signaling pathways in ES cell differen  tiation.
Finally,  we  recently  used  a  modification  of  ChIP-seq 
called chromatin-interaction analysis using pair end tag 
sequencing  (ChIA-PET),  in  which  all  chromatin 
interactions between estrogen receptor binding sites in 
the genome could be identified [22]. This three-dimen-
sional  chromatin  interaction  map  suggested  that  DNA 
topology might play a significant role in transcriptional 
regulation.
What more can we expect of ChIP-seq?
Criteria for quality of experimentation will shift as under-
standing of the power and the limitations of a technology 
mature. Moreover, the depth, detail and breadth of the 
analysis  will  depend  on  the  scientific  question  being 
asked. However, given what we now know, we can project 
what might be the new thresholds of acceptable experi-
mental  evidence  as  we  go  forward.  First,  are  the  anti-
bodies used for ChIP-seq specific? We understand that 
the  dynamics  of  binding  will  shift  according  to  the 
abundance of the primary DNA-binding protein and with 
its cofactors. So, the specific biochemical ‘states’, which 
include the levels of transcription factors of interest, will 
need to be taken into account in comparisons of different 
cell lines. There will be greater emphasis on the overlay of 
binding-site maps of multiple DNA-binding proteins to 
provide  a  more  comprehensive  picture  of  interactions 
and complex formation.
Published: 14 May 2010
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